SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
Summary: The authors hypothesized that despite similar cardiovascular event rates, the improved cardiovascular survival from sodium glucose transporter 2 (SGLT2) inhibition, seen clinically, could be via a direct cytoprotective effect, including protection against myocardial ischemia/reperfusion inj...
Main Authors: | Ven G. Lim, MBChB, Robert M. Bell, PhD, Sapna Arjun, PhD, Maria Kolatsi-Joannou, PhD, David A. Long, PhD, Derek M. Yellon, PhD, DSc |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-02-01
|
Series: | JACC: Basic to Translational Science |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2452302X18302699 |
Similar Items
-
Preventing the Cancer Patient of Today From Becoming the Heart Failure Patient of Tomorrow∗
by: Derek M. Yellon, PhD, DSc, et al.
Published: (2019-12-01) -
SGLT2 Inhibitor–Induced Sympathoinhibition
by: Lakshini Y. Herat, PhD, et al.
Published: (2020-02-01) -
3D Fusion Framework for Infarction and Angiogenesis Analysis in a
Myocardial Infarct Minipig Model
by: Xu Zhenzhen PhD, et al.
Published: (2017-05-01) -
Positive Effects of Illness following Acute Myocardial Infarction
by: Afrasiabifar A. PhD, et al.
Published: (2011-06-01) -
Difficulties of Portuguese Patients Following Acute Myocardial Infarction: Predictors of Readmissions and Unchanged Lifestyles
by: Sofia Nunes, PhD, et al.
Published: (2016-06-01)